Annual SGA
$17.87 M
-$13.47 M-42.98%
December 31, 2023
Summary
- As of February 12, 2025, RSLS annual SGA is $17.87 million, with the most recent change of -$13.47 million (-42.98%) on December 31, 2023.
- During the last 3 years, RSLS annual SGA has risen by +$2.65 million (+17.42%).
- RSLS annual SGA is now -46.19% below its all-time high of $33.21 million, reached on December 31, 2021.
Performance
RSLS SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$2.80 M
+$12.00 K+0.43%
September 30, 2024
Summary
- As of February 12, 2025, RSLS quarterly SGA is $2.80 million, with the most recent change of +$12.00 thousand (+0.43%) on September 30, 2024.
- Over the past year, RSLS quarterly SGA has dropped by -$1.05 million (-27.23%).
- RSLS quarterly SGA is now -81.98% below its all-time high of $15.55 million, reached on September 30, 2021.
Performance
RSLS Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$2.55 B
-$7.07 M-0.28%
September 30, 2024
Summary
- As of February 12, 2025, RSLS TTM SGA is -$2.55 billion, with the most recent change of -$7.07 million (-0.28%) on September 30, 2024.
- Over the past year, RSLS TTM SGA has dropped by -$2.57 billion (-12121.12%).
- RSLS TTM SGA is now -14774.80% below its all-time high of -$17.17 million.
Performance
RSLS TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
RSLS Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -43.0% | -27.2% | -10000.0% |
| 3 y3 years | +17.4% | -82.0% | -8834.6% |
| 5 y5 years | -7.2% | -22.1% | -10000.0% |
RSLS Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -46.2% | at low | -72.0% | +0.4% | -18.1% | at low |
| 5 y | 5-year | -46.2% | +17.4% | -82.0% | +0.4% | -40.0% | at low |
| alltime | all time | -46.2% | +670.5% | -82.0% | +85.5% | <-9999.0% | at low |
ReShape Lifesciences Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $2.80 M(+0.4%) | $11.48 M(-8.4%) |
| Jun 2024 | - | $2.79 M(-3.5%) | $12.53 M(-12.8%) |
| Mar 2024 | - | $2.89 M(-3.6%) | $14.36 M(-19.6%) |
| Dec 2023 | $17.87 M(-43.0%) | $3.00 M(-22.1%) | $17.87 M(-15.9%) |
| Sep 2023 | - | $3.85 M(-16.7%) | $21.24 M(-10.7%) |
| Jun 2023 | - | $4.62 M(-27.8%) | $23.78 M(-18.4%) |
| Mar 2023 | - | $6.40 M(+0.5%) | $29.16 M(-7.0%) |
| Dec 2022 | $31.34 M(-5.6%) | $6.37 M(-0.3%) | $31.34 M(-4.8%) |
| Sep 2022 | - | $6.39 M(-36.1%) | $32.91 M(-21.8%) |
| Jun 2022 | - | $10.00 M(+16.5%) | $42.07 M(+11.2%) |
| Mar 2022 | - | $8.59 M(+8.1%) | $37.83 M(+13.9%) |
| Dec 2021 | $33.21 M(+118.2%) | $7.94 M(-48.9%) | $33.21 M(+13.6%) |
| Sep 2021 | - | $15.55 M(+170.3%) | $29.24 M(+69.2%) |
| Jun 2021 | - | $5.75 M(+44.9%) | $17.28 M(+16.0%) |
| Mar 2021 | - | $3.97 M(+0.1%) | $14.90 M(-2.1%) |
| Dec 2020 | $15.22 M(-31.0%) | $3.97 M(+10.4%) | $15.22 M(-3.4%) |
| Sep 2020 | - | $3.59 M(+6.6%) | $15.75 M(-10.1%) |
| Jun 2020 | - | $3.37 M(-21.4%) | $17.52 M(-16.3%) |
| Mar 2020 | - | $4.29 M(-4.6%) | $20.94 M(-5.1%) |
| Dec 2019 | $22.07 M(+14.6%) | $4.50 M(-16.2%) | $22.07 M(+0.8%) |
| Sep 2019 | - | $5.36 M(-21.1%) | $21.89 M(+5.2%) |
| Jun 2019 | - | $6.79 M(+25.3%) | $20.81 M(+13.4%) |
| Mar 2019 | - | $5.42 M(+25.7%) | $18.35 M(-4.8%) |
| Dec 2018 | $19.26 M(-15.7%) | $4.31 M(+0.5%) | $19.26 M(-11.3%) |
| Sep 2018 | - | $4.29 M(-0.9%) | $21.71 M(-1.4%) |
| Jun 2018 | - | $4.33 M(-31.7%) | $22.02 M(-5.3%) |
| Mar 2018 | - | $6.34 M(-6.3%) | $23.26 M(+1.8%) |
| Dec 2017 | $22.85 M(+27.1%) | $6.76 M(+47.2%) | $22.85 M(+20.4%) |
| Sep 2017 | - | $4.60 M(-17.4%) | $18.98 M(+7.0%) |
| Jun 2017 | - | $5.56 M(-6.2%) | $17.74 M(-0.1%) |
| Mar 2017 | - | $5.93 M(+104.9%) | $17.77 M(-1.2%) |
| Dec 2016 | $17.98 M(-9.6%) | $2.89 M(-13.9%) | $17.98 M(-14.5%) |
| Sep 2016 | - | $3.36 M(-39.8%) | $21.03 M(-4.2%) |
| Jun 2016 | - | $5.59 M(-9.0%) | $21.96 M(+3.0%) |
| Mar 2016 | - | $6.14 M(+3.4%) | $21.31 M(+7.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2015 | $19.89 M(+36.6%) | $5.94 M(+38.5%) | $19.89 M(+16.8%) |
| Sep 2015 | - | $4.29 M(-13.1%) | $17.03 M(+6.2%) |
| Jun 2015 | - | $4.94 M(+4.4%) | $16.02 M(+4.4%) |
| Mar 2015 | - | $4.73 M(+53.9%) | $15.35 M(+5.4%) |
| Dec 2014 | $14.56 M(+6.6%) | $3.07 M(-6.5%) | $14.56 M(-2.9%) |
| Sep 2014 | - | $3.29 M(-22.9%) | $14.99 M(+0.5%) |
| Jun 2014 | - | $4.27 M(+8.4%) | $14.91 M(+6.5%) |
| Mar 2014 | - | $3.94 M(+12.3%) | $14.01 M(+2.6%) |
| Dec 2013 | $13.66 M(+14.2%) | $3.51 M(+9.3%) | $13.66 M(-0.8%) |
| Sep 2013 | - | $3.21 M(-4.5%) | $13.77 M(+1.6%) |
| Jun 2013 | - | $3.36 M(-6.3%) | $13.55 M(+6.4%) |
| Mar 2013 | - | $3.59 M(-0.7%) | $12.73 M(+6.5%) |
| Dec 2012 | $11.96 M(+39.4%) | $3.61 M(+20.8%) | $11.96 M(+14.5%) |
| Sep 2012 | - | $2.99 M(+17.7%) | $10.44 M(+6.5%) |
| Jun 2012 | - | $2.54 M(-9.7%) | $9.80 M(+5.1%) |
| Mar 2012 | - | $2.81 M(+34.3%) | $9.33 M(+8.7%) |
| Dec 2011 | $8.58 M(+11.8%) | $2.09 M(-11.0%) | $8.58 M(-1.0%) |
| Sep 2011 | - | $2.35 M(+14.0%) | $8.67 M(+7.5%) |
| Jun 2011 | - | $2.07 M(-0.1%) | $8.07 M(+3.7%) |
| Mar 2011 | - | $2.07 M(-5.2%) | $7.78 M(+1.3%) |
| Dec 2010 | $7.68 M(-11.0%) | $2.18 M(+24.6%) | $7.68 M(+4.5%) |
| Sep 2010 | - | $1.75 M(-1.5%) | $7.35 M(-11.4%) |
| Jun 2010 | - | $1.78 M(-9.6%) | $8.30 M(-4.5%) |
| Mar 2010 | - | $1.97 M(+6.0%) | $8.69 M(+0.7%) |
| Dec 2009 | $8.63 M(+0.4%) | $1.85 M(-31.4%) | $8.63 M(-2.6%) |
| Sep 2009 | - | $2.70 M(+24.6%) | $8.86 M(+10.4%) |
| Jun 2009 | - | $2.17 M(+13.8%) | $8.02 M(-1.8%) |
| Mar 2009 | - | $1.91 M(-8.4%) | $8.17 M(-5.0%) |
| Dec 2008 | $8.60 M(+23.3%) | $2.08 M(+11.3%) | $8.60 M(+7.1%) |
| Sep 2008 | - | $1.87 M(-19.2%) | $8.03 M(+0.6%) |
| Jun 2008 | - | $2.31 M(-0.8%) | $7.98 M(+40.9%) |
| Mar 2008 | - | $2.33 M(+54.4%) | $5.66 M(+70.0%) |
| Dec 2007 | $6.97 M(+85.4%) | $1.51 M(-17.1%) | $3.33 M(+82.9%) |
| Sep 2007 | - | $1.82 M | $1.82 M |
| Dec 2006 | $3.76 M(+62.1%) | - | - |
| Dec 2005 | $2.32 M | - | - |
FAQ
- What is ReShape Lifesciences annual SGA?
- What is the all time high annual SGA for ReShape Lifesciences?
- What is ReShape Lifesciences annual SGA year-on-year change?
- What is ReShape Lifesciences quarterly SGA?
- What is the all time high quarterly SGA for ReShape Lifesciences?
- What is ReShape Lifesciences quarterly SGA year-on-year change?
- What is ReShape Lifesciences TTM SGA?
- What is the all time high TTM SGA for ReShape Lifesciences?
- What is ReShape Lifesciences TTM SGA year-on-year change?
What is ReShape Lifesciences annual SGA?
The current annual SGA of RSLS is $17.87 M
What is the all time high annual SGA for ReShape Lifesciences?
ReShape Lifesciences all-time high annual SGA is $33.21 M
What is ReShape Lifesciences annual SGA year-on-year change?
Over the past year, RSLS annual SGA has changed by -$13.47 M (-42.98%)
What is ReShape Lifesciences quarterly SGA?
The current quarterly SGA of RSLS is $2.80 M
What is the all time high quarterly SGA for ReShape Lifesciences?
ReShape Lifesciences all-time high quarterly SGA is $15.55 M
What is ReShape Lifesciences quarterly SGA year-on-year change?
Over the past year, RSLS quarterly SGA has changed by -$1.05 M (-27.23%)
What is ReShape Lifesciences TTM SGA?
The current TTM SGA of RSLS is -$2.55 B
What is the all time high TTM SGA for ReShape Lifesciences?
ReShape Lifesciences all-time high TTM SGA is -$17.17 M
What is ReShape Lifesciences TTM SGA year-on-year change?
Over the past year, RSLS TTM SGA has changed by -$2.57 B (-12121.12%)